markets
Merck beats quarterly estimates, raises outlook as injectable Keytruda gains
Merck reported third-quarter revenue of $18.1 billion and adjusted earnings of $2.49 a share, exceeding analyst forecasts. Stronger sales of Keytruda, including…
2 min readvia CNBC Markets